The study found that W6134 and XY018 upregulate the expression of key inflammatory genes CXCL10 and MECOM, while genes related to TNF and IL-17 signaling pathways are significantly upregulated, indicating that W6134 and XY018 may exert their anticancer effects by modulating the aforementioned pathways, thereby influencing the growth of cancer cells. This evidence concerns the gene IL17A and cancer.